Navigation Links
Local Research Foundation Achieves Milestone in Fight Against Cancer
Date:10/23/2008

CHRISTUS Stehlin Foundation for Cancer Research Develops Innovative

Anticancer Drug

HOUSTON, Oct. 23 /PRNewswire/ -- Almost everyone knows the devastation that cancer brings to families, workplaces and communities, and many Houstonians are aware of well-known local cancer treatment institutions. Few, however, may be familiar with the CHRISTUS Stehlin Foundation for Cancer Research, a nationally recognized leader in cancer research located in Houston, which recently achieved a milestone in their battle against cancer.

The CHRISTUS Stehlin Foundation recently received word from the Food and Drug Administration that CZ48, a promising anticancer drug they discovered and developed, was approved to begin Phase I (human) clinical trials. This is a large step in the journey to offer this potentially lifesaving drug to people suffering from cancer.

This is a remarkable accomplishment, since past records show that for every 5,000 to 10,000 oncology compounds discovered, only 250 make it to pre-clinical phases, and only five (one-tenth of one percent) are approved by the FDA for these human studies.

CZ48 is a derivative of extracts from a Chinese tree, the Camptotheca Acuminata, which more than 45 years ago showed potent anticancer activity against a type of mouse leukemia. The Stehlin Foundation has been researching cancer treatment with the Camptothecin family of compounds since 1988, and as a pioneer in the development of the Camptothecin family of drugs, has synthesized and tested more than 200 Camptothecin derivatives. In fact, the New York Academy of Science wrote, "Camptothecins can be envisioned as the ultimate anticancer drugs when fully developed."

The first phase of the trial has begun at the University of New Mexico Cancer Center in Albuquerque, N.M., and plans are also under way to offer the trial at Vanderbilt-Ingram Cancer Center in Nashville, Tenn. This phase of the clinical trial process is expected to last 12-15 months.

The CHRISTUS Stehlin Foundation is hopeful about the results of these clinical trials, as CZ48 has been shown in pre-clinical studies to exhibit a broad spectrum of anticancer activity against a wide array of human cancers growing in nude mice with a striking lack of toxicity. CZ48 is also innovative in that it can be taken orally, and pre-clinical studies indicate that it has very few side effects. This makes its appeal even stronger for human cancer treatment.

"We have always felt that CZ48 holds tremendous promise as a cancer treatment, which is why we have worked so diligently to make it available," said Dr. Beppino Giovanella, laboratory director at the CHRISTUS Stehlin Foundation for Cancer Research. "It is our hope that CZ48 will continue the legacy of the foundation and bring renewed hope and life to people around the world who suffer from cancer."

About the CHRISTUS Stehlin Foundation for Cancer Research

The CHRISTUS Stehlin Foundation for Cancer Research has developed and supported many innovative and life-saving treatments for patients with cancer, including being some of the first to recommend a lumpectomy for women with breast cancer. The CHRISTUS Foundation also innovated the use of nude mice in cancer research. Nude mouse tests are now the final, non-human studies required by the National Cancer Institute for determining the effectiveness of potential anticancer agents. Many scientists around the world consider the nude mouse one of the 20th century's most significant breakthroughs in cancer research.

The foundation was established by Dr. John S. Stehlin Jr., a cancer specialist and surgeon, with a specific and urgent mission: to find and develop the most effective treatments for the patient who suffered from cancer in the shortest period of time. In reaction to his mounting frustration with the traditional approach to cancer treatment, he developed a tripartnership concept between clinician, research scientist and patient, in which everyone works together to provide the best overall treatment. The CHRISTUS Stehlin Foundation conducts research that can be applied directly to improving the treatment of the patient with cancer, and all research is clinically oriented. Visit them on the web at http://www.stehlin.org.

About CHRISTUS Health

CHRISTUS Health, an international Catholic, faith-based, not-for-profit health system, is headquartered in Dallas and is comprised of almost 350 services and facilities, including more than 50 hospitals and long-term care facilities, 175 clinics and outpatient centers and dozens of other health ministries and ventures in more than 60 cities in Texas, Arkansas, Louisiana, Missouri, New Mexico, Georgia, Utah and Mexico. The system employs more than 28,000 Associates -- including 8,000 physicians on facility medical staffs -- that provide care and support for patients. CHRISTUS Health is listed among the top ten Catholic health systems in the U.S., and among the nation's Top 100 integrated Healthcare Networks.


'/>"/>
SOURCE CHRISTUS Stehlin Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
2. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
3. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
4. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
5. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases
7. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... ZIONA, Israel , May ... regenerative medicine company utilizing its proprietary plant-based rhCollagen technology ... received authorization from the Chief Scientist of ... 50% of its NIS 12 million development project for ... measurably higher than last year,s authorized grant, which totaled ...
(Date:5/31/2016)... -- 194 Mitgliedsstaaten verpflichten sich ... viraler Hepatitis    Am 28. Mai ... Hepatitis bis 2030 zu eliminieren. Bei der ... sich die Staaten einstimmig dafür entschieden, die erste ... Strategy) zu verabschieden, was das bisher weltweit größte ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... IL (PRWEB) , ... May 31, 2016 , ... The ... and executive committee members: , David G. Lewallen, MD, began his term as ... past president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on ... broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate ... calls the country’s “modern medical money maelstrom.” , During the interview with Mr. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... apply information technology solutions to the healthcare industry, The University of Scranton is ... offers an accelerated path to a career in rapidly growing field of healthcare ...
(Date:5/30/2016)... ... May 30, 2016 , ... "This plugin comes with ... Austin - CEO of Pixel Film Studios. , TransPack Volume 7 features ... Choose from abstract transitions to more simple wipes with blur & drop shadow ...
Breaking Medicine News(10 mins):